![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jeffrey Trocio, Virginia M Rosen, Anu Gupta, Oluwaseyi Dina, Lien Vo, Patrick Hlavacek & Lisa Rosenblatt. (2019) Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings. ClinicoEconomics and Outcomes Research 11, pages 23-49.
Read now
Read now
Michael Streiff, Dejan Milentijevic, Keith R. McCrae, François Laliberté, Dominique Lejeune, Patrick Lefebvre, Jeff Schein & Alok A. Khorana. (2019) Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants. Journal of Medical Economics 22:11, pages 1134-1140.
Read now
Read now
Philip S. Wells, Anthonie W. A. Lensing, Lloyd Haskell, Bennett Levitan, François Laliberté, Michael Durkin, Veronica Ashton, Yongling Xiao, Concetta Crivera, Dominique Lejeune, Jeff Schein & Patrick Lefebvre. (2018) Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. Journal of Medical Economics 21:6, pages 587-594.
Read now
Read now
Christine G. Kohn, Gregory J. Fermann, W. Frank Peacock, Phil S. Wells, Christopher W. Baugh, Veronica Ashton, Concetta Crivera, Jeff R. Schein, Peter Wildgoose & Craig I. Coleman. (2017) Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. Current Medical Research and Opinion 33:9, pages 1697-1703.
Read now
Read now
Aarti A. Patel, Kristine Ogden, Samir H. Mody & Brahim Bookhart. (2015) The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. Journal of Medical Economics 18:5, pages 323-332.
Read now
Read now
Articles from other publishers (33)
Meixuan Li, Jing Li, Xiaoqin Wang, Xu Hui, Qi Wang, Shitong Xie, Peijing Yan, Jinhui Tian, Jianfeng Li, Ping Xie, Kehu Yang & Liang Yao. (2023) Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism. Cochrane Database of Systematic Reviews 2023:4.
Crossref
Crossref
Xiaoqin Wang, Yanfang Ma, Xu Hui, Meixuan Li, Jing Li, Jinhui Tian, Qi Wang, Peijing Yan, Jianfeng Li, Ping Xie, Kehu Yang & Liang Yao. (2023) Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews 2023:4.
Crossref
Crossref
Ayobami S. Ogunsola, Kameron Farhadi, Udeh C. Mercy, Faith Elenwa, Rukayyah M. Karaye, Muhammad Jaafar Baba, Eniola A. Olatunji, Ismaeel Yunusa & Ibraheem M. Karaye. (2023) Analysis of contemporary mortality trends in pulmonary embolism, United States, 1999–2020. Thrombosis Research 223, pages 53-60.
Crossref
Crossref
W. Frank Peacock, Craig Coleman, Phil Wells, Gregory Freeman, Li Wang, Onur Baser, Jeff Schein & Concetta Crivera. (2023) Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. Journal of Health Economics and Outcomes Research, pages 160-173.
Crossref
Crossref
B. Boietti, S. Fili, V. Peuchot, A. Tabares, F. Vázquez & E. Gándara. (2021) Impact of the use of rivaroxaban in the length of stay of patients treated for acute venous thromboembolism in a developing country. Thrombosis Research 204, pages 143-145.
Crossref
Crossref
Adesola Adedeji, Onyinye Chukwura, Taiye Obafemi, Stephen B. McNulty & Justin P. Reinert. (2020) Anticoagulation Strategies in the Management of Lemierre Syndrome: A Systematic Review of the Literature. Annals of Pharmacotherapy 55:5, pages 658-665.
Crossref
Crossref
Jason Filopei, Eric E. Bondarsky, Madeline Ehrlich, Marjan Islam, Gargi Bajpayee, Daniel Pang, Adil Shujaat, John Rowland & David J. Steiger. (2020) Reducing length of stay with the direct oral anti-coagulants in low and intermediate risk pulmonary embolism: a single center experience. Journal of Thrombosis and Thrombolysis 50:2, pages 399-407.
Crossref
Crossref
Raein Ghazvinian, Johan Elf, Sofia LöfvendahlJan HolstAnders Gottsäter. (2020) Outpatient Treatment in Low-Risk Pulmonary Embolism Patients Receiving Direct Acting Oral Anticoagulants Is Associated With Cost Savings. Clinical and Applied Thrombosis/Hemostasis 26, pages 107602962093735.
Crossref
Crossref
W. Frank Peacock, Craig I. Coleman, Phil Wells, Gregory J. Fermann, Li Wang, Onur Baser, Jeff Schein & Concetta Crivera. (2019) Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. Journal of Health Economics and Outcomes Research 6:3, pages 160-173.
Crossref
Crossref
Lorenzo G. Mantovani, Sylvia Haas, Reinhold Kreutz, Kerstin Folkerts, Martin Gebel, Danja Monje, Jonas Schneider, Martin van Eickels, Kurtulus Sahin, Elizabeth Zell, Walter Ageno & Alexander G.G. Turpie. (2019) Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis. European Journal of Internal Medicine 61, pages 29-33.
Crossref
Crossref
Tammy J Bungard, Bruce Ritchie, Jennifer Bolt & William M Semchuk. (2018) Anticoagulant therapies for acute venous thromboembolism among a cohort of patients discharged from Canadian urban and rural hospitals. BMJ Open 8:10, pages e022065.
Crossref
Crossref
Lara M. Groetzinger, Taylor J. Miller, Ryan M. Rivosecchi, Roy E. Smith, Mark T. Gladwin & Belinda N. Rivera-Lebron. (2018) Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis. Clinical and Applied Thrombosis/Hemostasis 24:6, pages 908-913.
Crossref
Crossref
Luke S G E Howard, Steven Barden, Robin Condliffe, Vincent Connolly, Christopher W H Davies, James Donaldson, Bernard Everett, Catherine Free, Daniel Horner, Laura Hunter, Jasvinder Kaler, Catherine Nelson-Piercy, Emma O’Dowd, Raj Patel, Wendy Preston, Karen Sheares & Campbell Tait. (2018) British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). Thorax 73:Suppl 2, pages ii1-ii29.
Crossref
Crossref
Hisham Badreldin. (2018) Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study. Journal of Thrombosis and Thrombolysis 46:1, pages 16-21.
Crossref
Crossref
Yongzhe Hong, Sola Mansour, Ghazi Alotaibi, Cynthia Wu & Michael Sean McMurtry. (2018) Effect of anticoagulants on admission rates and length of hospital stay for acute venous thromboembolism: A systematic review of randomized control trials. Critical Reviews in Oncology/Hematology 125, pages 12-18.
Crossref
Crossref
Melissa Coombs & Benjamin Fox. (2017) Outpatient Treatment of Pulmonary Embolism: a Practical Guide. Current Emergency and Hospital Medicine Reports 6:1, pages 31-36.
Crossref
Crossref
Amanda N. Basto, Nathan P. Fewel, Kim Vo, Eileen M. Stock & Mia Ta. (2017) Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge. Journal of Thrombosis and Thrombolysis 45:1, pages 51-55.
Crossref
Crossref
Lindsay Robertson, Su Ern Yeoh & Ahmad Ramli. (2017) Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. Cochrane Database of Systematic Reviews 2017:12.
Crossref
Crossref
Catherine A Saint, Michelle R Castelli, Andrew J Crannage, Zachary A Stacy & Erin K Hennessey. (2017) Comparison of hospital length of stay in patients treated with non–vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism. SAGE Open Medicine 5, pages 205031211771962.
Crossref
Crossref
Craig I. Coleman, Gregory J. Fermann, Erin R. Weeda, Philip S. Wells, Veronica Ashton, Concetta Crivera, Thomas J. Bunz, Peter Wildgoose, Jeff R. Schein & W. Frank Peacock. (2016) Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?. Clinical and Applied Thrombosis/Hemostasis 23:7, pages 830-837.
Crossref
Crossref
George Gourzoulidis, Georgia Kourlaba, John Kakisis, Mitiadis Matsagkas, George Giannakoulas, Konstantinos I. Gourgoulianis, Theodoros Vassilakopoulos & Nikos Maniadakis. (2017) Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece. Clinical Drug Investigation 37:9, pages 833-844.
Crossref
Crossref
Luca Masotti, Vieri Vannucchi, Marzia Poggi & Giancarlo Landini. (2017) Trends in length of hospital stay in acute pulmonary embolism over the years. What is changing in the era of direct oral anticoagulants?. Journal of Cardiovascular Medicine 18:7, pages 556-559.
Crossref
Crossref
Li Wang, Onur Baser, Phil Wells, W. Frank Peacock, Craig I. Coleman, Gregory J. Fermann, Jeff Schein & Concetta Crivera. (2017) Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. Clinical Therapeutics 39:7, pages 1426-1436.e2.
Crossref
Crossref
Franco Piovella & Diana I. Iosub. (2017) Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism. Thrombosis Research 152, pages 87-92.
Crossref
Crossref
Erin R. Weeda, Philip S. Wells, W. Frank Peacock, Gregory J. Fermann, Christopher W. Baugh, Veronica Ashton, Concetta Crivera, Peter Wildgoose, Jeff R. Schein & Craig I. Coleman. (2016) Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Internal and Emergency Medicine 12:3, pages 311-318.
Crossref
Crossref
Erin R. Weeda, W. Frank Peacock, Gregory J. Fermann, Christopher W. Baugh, Philip S. Wells, Veronica Ashton, Concetta Crivera, Peter Wildgoose, Jeff R. Schein & Craig I. Coleman. (2017) Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. International Journal of Clinical Practice 71:1, pages e12915.
Crossref
Crossref
Jay M. Margolis, Steven Deitelzweig, Jeffrey Kline, Oth Tran, David M. Smith, Concetta Crivera, Brahim Bookhart & Jeff Schein. (2016) Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin. Clinical Therapeutics 38:11, pages 2496-2503.
Crossref
Crossref
Jay M. Margolis, Steven Deitelzweig, Jeffrey Kline, Oth Tran, David M. Smith, Brahim Bookhart, Concetta Crivera & Jeff Schein. (2016) Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions. Journal of the American Heart Association 5:10.
Crossref
Crossref
Erin R. Weeda, Christine G. Kohn, W. Frank Peacock, Gregory J. Fermann, Concetta Crivera, Jeff R. Schein & Craig I. Coleman. (2016) Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:10, pages 1109-1115.
Crossref
Crossref
Anish Desai, Amishi Desai, Rose Calixte, Malaygiri Aparnath, Alexander Hindenburg, Steve Salzman & Joseph P. Mathew. (2016) Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism. Lung 194:4, pages 605-611.
Crossref
Crossref
Stavros V. Konstantinides. (2017) Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?. Thrombosis and Haemostasis 115:02, pages 233-235.
Crossref
Crossref
Kirsten M. Roberts, Tamara B. Knight, Eimeira Padilla-Tolentino, Manasa Murthy & Evan J. Peterson. (2015) Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study. Thrombosis 2015, pages 1-6.
Crossref
Crossref
Lindsay Hom & Diana M. Sobieraj. (2015) The impact of initiating rivaroxaban versus low-molecular weight heparin plus warfarin in patients admitted to the hospital for venous thromboembolism. International Journal of Cardiology 198, pages 87-88.
Crossref
Crossref